Emcure Pharmaceuticals IPO: Subscription Details, GMP, and Investment Insights
IPO News: Emcure Pharmaceuticals IPO opened for subscription on July 3, having raised ₹582 crore from 48 anchor investors at an upper price range of ₹1,008 per share. The IPO, backed by Bain Capital, closes on July 5, with a price band set at ₹960-1,008 per share.
Company Overview
Emcure Pharmaceuticals, based in Pune, develops, produces, and markets a wide range of pharmaceutical products globally. The company has a robust R&D infrastructure and a diverse product portfolio.
Emcure Pharmaceuticals IPO Allocation
Qualified Institutional Investors (QIBs): 50% of the issue size
Retail Investors: 35%
Non-Institutional Investors: 15%
Employee Portion: 108,900 equity shares
Emcure Pharmaceuticals IPO Investment Details
Investors can bid for a minimum of 14 shares and additional shares in multiples of 14. The Emcure Pharmaceuticals IPO includes a fresh issue of ₹800 crore and an offer for sale (OFS) of ₹1,151 crore by existing promoters and shareholders.
Selling Shareholders
Prominent selling shareholders include Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, Samit Satish Mehta, and others, along with BC Investments IV.
Lead Managers and Registrar
The book-running lead managers are Axis Capital Limited, J.P. Morgan India Private Limited, Jefferies India Private Limited, and Kotak Mahindra Capital Company Limited. Link Intime India Private Ltd. is the registrar.
Emcure Pharmaceuticals IPO Grey Market Premium
Emcure Pharmaceuticals IPO GMP for Emcure Pharma IPO is +₹299, indicating an expected listing price of ₹1,307 per share, which is 29.66% higher than the IPO price of ₹1,008.
Emcure Pharmaceuticals IPO Key Considerations
While Emcure has a strong market presence and a diverse product range, potential investors should consider the regulatory challenges in the pharmaceutical sector and the company’s dependence on partners for distribution. Despite recent dips in profitability due to depreciation and interest costs, the company’s overall growth and brand establishment remain strong.
